Sunsai Pharma Equipments Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 18 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.00 M
as on 24-10-2024
- Revenue -26.08%
(FY 2023)
- Profit 153.08%
(FY 2023)
- Ebitda 619.47%
(FY 2023)
- Net Worth 7.59%
(FY 2023)
- Total Assets 16.37%
(FY 2023)
About Sunsai Pharma Equipments
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.00 M.
Priyanka Bhatte and Meghan Bhatte serve as directors at the Company.
- CIN/LLPIN
U24239MH2006PTC165376
- Company No.
165376
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Nov 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sunsai Pharma Equipments Private Limited offer?
Sunsai Pharma Equipments Private Limited offers a wide range of products and services, including Chemical Plants & Machinery, Ointment Manufacturing Plant, Pharmaceutical Machinery & Equipment, Pharmaceutical Machines, Dryers & Evaporators, Medical Air Dryer, Pharmaceutical Dryers, Tablet Making Machines, Industrial Mixers & Homogenizers, Powder Mixers.
Who are the key members and board of directors at Sunsai Pharma Equipments?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meghan Bhatte  | Director | 01-Nov-2017 | Current |
| Priyanka Bhatte | Director | 06-Nov-2006 | Current |
Financial Performance of Sunsai Pharma Equipments.
Sunsai Pharma Equipments Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 26.08% decrease. The company also saw a substantial improvement in profitability, with a 153.08% increase in profit. The company's net worth moved up by a moderate rise of 7.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sunsai Pharma Equipments?
In 2023, Sunsai Pharma Equipments had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Ltd Creation Date: 05 Mar 2013 | ₹7.00 M | Open |
How Many Employees Work at Sunsai Pharma Equipments?
Sunsai Pharma Equipments has a workforce of 49 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sunsai Pharma Equipments, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sunsai Pharma Equipments's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
